Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | PARP10 | Q53GL7 | 3/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 7/20 | 0.34 |
| ▸ | PARP15 | Q460N3 | 2/20 | 0.34 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.31 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4019647 | 0.89 | FPR2 (0.38) | FPR2SCN9ADRD4PARP10HDAC6 | |
| SCHEMBL4018141 | 0.79 | PARP10 (0.44) | SCN9APARP10PARP15 | |
| SCHEMBL4016203 | 0.78 | PARP10 (0.39) | SCN9APARP10PARP15MAOAMAOB | |
| SCHEMBL4014221 | 0.77 | MEN1 (0.36) | PARP10PARP15MAOAMAOB | |
| SCHEMBL4018367 | 0.76 | ATM (0.44) | — | |
| SCHEMBL4018676 | 0.76 | PARP10 (0.41) | PARP10PARP15EGLN2EGLN1MAOA | |
| SCHEMBL4018723 | 0.74 | OPRM1 (0.41) | SCN9APARP10PARP15 | |
| SCHEMBL4020004 | 0.74 | FYN (0.42) | PARP10PARP15 | |
| SCHEMBL4017274 | 0.67 | PPARD (0.39) | PARP10PARP15 | |
| SCHEMBL4016168 | 0.66 | ATM (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7618996-B2 | Diaryl ether derivatives and uses thereof | PFIZER INC. (US) | 2009-11-17 | — | — | US | claimed |
| EP-2064199-A1 | DIARYL ETHER DERIVATIVES AND USES THEREOF | Pfizer Products Inc. (US) | 2009-06-03 | — | — | EP | claimed |
| WO-2008032156-A1 | DIARYL ETHER DERIVATIVES AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2008-03-20 | — | — | WO | claimed |
| US-20080070887-A1 | Diaryl Ether Derivatives and Uses Thereof | PFIZER INC | 2008-03-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070887-A1 | Diaryl Ether Derivatives and Uses Thereof | OPRD1, OPRK1, OPRL1 | FPR2 875/4885SCN9A 819/4885DRD4 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.